4+ day, 4+ hour ago   (207+ words) That’s why the Novel CNS Biomarkers Summit Europe comes at a timely moment, bringing together Europe's leading biomarker, translational medicine, neuroscience and clinical development experts to tackle one of the industry's biggest challenges: improving clinical trial success in CNS drug…...

5+ day, 7+ hour ago   (565+ words) An AI-powered imaging tool developed by Brainomix has been used to enrich data from a phase 2a trial of Endeavor BioMedicines' hedgehog pathway inhibitor taladegib, in development for idiopathic pulmonary fibrosis (IPF). The post hoc analysis of the study showed that…...

6+ day, 6+ hour ago   (809+ words) Drug development is an inherently risky endeavour, with the average probability of approval for a drug entering Phase I studies now sitting at just 6.7%. While much of this can be attributed to lack of efficacy, factors such as poor clinical…...

2+ week, 2+ hour ago   (477+ words) An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients with chronic heart failure. Data from the phase 2b LUMINARA trial, reported at the ESC 2026 congress and simultaneously published in the journal Circulation, suggest…...

3+ week, 3+ day ago   (386+ words) Paris, France-based Bioptimus, a global AI biotech company, has announced a partnership with Cancer Research Horizons, the innovation engine of Cancer Research UK, to advance AI-powered precision medicine. The agreement allows Bioptimus to access S:CORT (Stratification in COloRectal cancer Trial),…...

3+ week, 6+ day ago   (175+ words) The Medicines and Healthcare products Regulatory Agency (MHRA) has published its position paper clarifying how microbiome-based medicines can be made available for patients in the UK. The purpose of the position paper is to encourage the development and licensing of…...

1+ mon, 1+ day ago   (487+ words) Skylark Bio has started dosing patients in a phase 1/2 trial of SKY-GJB2, a one-shot gene therapy designed to treat GJB2-mediated hearing loss, the most common form of genetic deafness in children. The first patient has been treated with SKY-GJB2, which…...

1+ mon, 2+ day ago   (493+ words) A therapy room used to deliver the one-off, therapist-assisted treatment. Psychedelic drug developer Definium Therapeutics has reported positive phase 3 results with its LSD-based therapy, DT120, in anxiety, sparking a 15% rise in its share price. Definium – which was formerly known as MindMed…...

1+ mon, 2+ day ago   (506+ words) A kidney transplant patient with a rare, multidrug-resistant (MDR) infection has become the first to be treated using an adjunctive bacteriophage therapy developed by Denmark's SNIPR Biome. The SNIPR001 therapy takes the form of a bacteriophage – a virus that only infects…...

1+ mon, 4+ day ago   (477+ words) Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy epilepsy drug developer Actio Biosciences in a deal that includes an upfront payment of $820 million. Privately-held Actio is developing a small-molecule KCNT1 ion channel inhibitor, codenamed…...